Biotech and Pharmaceuticals Biotechnology

More

  • Fear trades: Copper, biotech & shorting tech

    CNBC's Dominic Chu; Jim Iuorio, Managing Director at TJM Institutional Services; and David Seaburg, Managing Director and Head of Sales & Trading at Cowen & Company, discuss top fear trades on this Friday the 13th.

  • Tiny ingestible robot made of meat that can unfold in stomach

    MIT researchers are developing a device that could one day help patch internal wounds, deliver medicine or remove accidentally swallowed objects from the stomach.

  • Cellectis' gene editing breakthrough: CEO

    Dr. Andre Choulika, Cellectis CEO, discusses how gene editing could lead to a new way to fight cancer.

  • Healthy biotech M&A?

    Discussing the impact of biotech deals on the sector overall, and whether Sanofi's offer for Medivation will pass, with Michael King, JMP Securities, and Les Funtleyder, E Squared Capital.

  • DNA Research

    Sam Isaly, OrbiMed Advisors founder, discusses health care industry stock picks.

  • Shkreli thanks supporters as he heads into court

    Martin Shkreli, former CEO of Turing Pharmaceuticals, will appear in at the U.S. District Court in Brooklyn Tuesday following December's seven-count indictment, reports CNBC's Meg Tirrell.

  • Biotech healthcare lab

    GlaxoSmithKline CEO Andrew Whitty thinks his company's success has been a product of being patient and investing in innovation.

  • Focused scientist examining petri dishes

    Sarepta Therapeutics shares soared Monday after the stock was upgraded to "outperform" at Oppenheimer.

  • Jesper Brandgaard, CFO of Novo Nordisk, discusses the pharmaceutical company's earnings results and the impact of the declining dollar.

  • Gilead Sciences Inc

    Analysts expected Gilead to report earnings of about $3.15 a share on $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.

  • April 28- AbbVie Inc said it would buy privately held oncology company Stemcentrx in a deal valued at $5.8 billion to expand its portfolio of drugs to treat cancer. AbbVie also lowered it full-year adjusted profit forecast to $4.62- $4.82 per share from $4.90- $5.10. AbbVie had bought Pharmacyclics Inc for about $21 billion in March last year, giving it access to...

  • Options Action: Big biotech, big moves?

    Potential market cap swings in biotech with CNBC contributor Dan Nathan.

  • biopharmaceuticals

    Sarepta was down sharply a day after an FDA advisory committee voted against recommending the company's Duchenne muscular dystrophy drug.

  • Sarepta a wild stock 'not for everyone': Najarian

    Discussing the play on Sarepta Therapeutics as its Duchenne muscular dystrophy drug sees pressure from FDA, with the FMHR traders.

  • VRX vs. PRGO for CEO

    CNBC's Meg Tirrell reports on the possibility of Perrigo CEO Joseph Papa heading over to Valeant, as well as biotech firm Interxon feeling some pressure after the release of a report calling it 'the new Theranos.'

  • CAMBRIDGE, England, April 22- AstraZeneca, working with genome pioneer Craig Venter, is launching a massive gene hunt in the most comprehensive bet yet by a pharmaceutical firm on the potential of genetic variations to unlock routes to new medicines. AstraZeneca will work with Venter's U.S. company Human Longevity Inc, which will sequence the genomes, including...

  • Nasdaq CEO's outlook on bank earnings, IPOs &more

    Robert Greifeld, Nasdaq CEO, discusses bank earnings, the IPO market, and more at the eMerge Americas conference.

  • Federal regulators are investigating blood-testing start-up Theranos over whether it misled investors.

  • Adam Parker recommends biotech

    Adam Parker, Morgan Stanley chief U.S. equity strategist, thinks biotech and pharma look attractive, in discussing his market forecast.

  • Sean Parker speaking at the 2015 CGI Annual Meeting in New York.

    Following his announcement to donate $250 million for cancer research, Sean Parker joined CNBC to discuss his initiative.